Stemline Therapeutics Inc (NASDAQ:STML) COO Kenneth Hoberman sold 14,040 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $13.93, for a total value of $195,577.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kenneth Hoberman also recently made the following trade(s):

  • On Friday, December 15th, Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total value of $169,351.74.
  • On Monday, December 18th, Kenneth Hoberman sold 11,983 shares of Stemline Therapeutics stock. The stock was sold at an average price of $14.18, for a total value of $169,918.94.

Shares of Stemline Therapeutics Inc (STML) opened at $14.10 on Monday. Stemline Therapeutics Inc has a fifty-two week low of $5.50 and a fifty-two week high of $16.20.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.11). Stemline Therapeutics had a negative return on equity of 75.50% and a negative net margin of 4,689.63%. equities research analysts anticipate that Stemline Therapeutics Inc will post -2.71 EPS for the current year.

Hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $102,000. Nationwide Fund Advisors boosted its holdings in shares of Stemline Therapeutics by 7.2% during the second quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 855 shares during the last quarter. State of Wisconsin Investment Board acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $147,000. Alliancebernstein L.P. acquired a new stake in shares of Stemline Therapeutics during the second quarter worth $178,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Stemline Therapeutics by 40.1% during the second quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock worth $178,000 after purchasing an additional 5,522 shares during the last quarter. Institutional investors and hedge funds own 50.24% of the company’s stock.

Several equities analysts have weighed in on STML shares. Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. HC Wainwright raised their price target on Stemline Therapeutics from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, November 1st. BidaskClub downgraded Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Finally, Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Stemline Therapeutics has an average rating of “Buy” and a consensus target price of $33.75.

COPYRIGHT VIOLATION WARNING: “Stemline Therapeutics Inc (STML) COO Kenneth Hoberman Sells 14,040 Shares” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/15/stemline-therapeutics-inc-stml-coo-kenneth-hoberman-sells-14040-shares.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.